Skip to main content
. 2010 May 29;95(10):1705–1712. doi: 10.3324/haematol.2010.025338

Figure 2.

Figure 2.

Progression-free survival and overall survival by risk group. (A) Progression-free survival. Poor risk: >10% TP53 loss. Intermediate risk: ≤10% TP53 loss and at least one of: unmutated IGHV genes, IGHV3-21 usage, beta-2 microglobulin >4 mg/L, 11q loss >5%. Good risk: ≤10% TP53 loss, none of the intermediate risk factors and mutated IGHV genes. (B) Overall survival.